Brochure: Welcome to bioprocessing – pathways for pioneers
Posted: 21 June 2021 | Merck | No comments yet
The journey from large molecule to approved biotherapeutic is long, costly, complex and fraught with risk – yet rewards for success are substantial.
From bench to full-scale production, we offer a full range of raw materials, tools, services and technologies, from off-the-shelf to customisable, to accelerate development, optimisation and scale-up of your process. Our in-house experts have decades of bioprocessing experience and will collaborate with you to tackle any development and processing challenges, as well as provide quality testing services.
Related content from this organisation
- MSD set to acquire novel antibody for B-cell malignancies
- Novel immunotherapy combination approved for endometrial cancer
- Innovating small molecule injectables: market forecast to 2033
- Ophthalmology acquisition to advance tri-specific antibody
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
Related topics
Biologics, Biopharmaceuticals, Bioprocessing, Biosimilars, Chromatography, Excipients, Formulation, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Outsourcing, Research & Development (R&D), Supply Chain, Vaccines
